The affordable growth screen looks for companies that combine strong expansion with a reasonable valuation, while still passing basic quality checks on profitability and financial health. PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX) (NASDAQ:PTGX) stands out under this methodology because its growth metrics are well above average, and despite a demanding headline earnings multiple, the stock still screens as attractively valued within its biotech peer group.
What the affordable growth screen targets
The idea behind an affordable growth strategy is to avoid paying any price for momentum. Fast-growing companies often trade at rich multiples, but the screen tries to identify situations where the market has not fully priced in future expansion. In practice, that means looking for:
- Strong historical and expected earnings growth
- Revenue growth that is steady and preferably accelerating
- A valuation that is reasonable relative to industry peers
- Solid enough profitability and balance sheet health to reduce downside risk
Protagonist Therapeutics clears most of those hurdles. ChartMill gives the company a growth rating of 8 out of 10 and a health rating of 8 out of 10, with a more moderate profitability rating of 5 out of 10 and a valuation rating of 5 out of 10. The overall fundamental rating of 6 out of 10 reflects a business that is still clinical-stage, but the underlying metrics are notable for a company at this stage of development.
Growth is the main driver
The growth case for Protagonist is supported by both recent results and forward estimates. The company grew revenue by 34.81% over the last year and grew earnings per share by 47.14% in the same period. Analysts expect that momentum to continue, with EPS growth of 36.32% per year and revenue growth of 68.61% per year on average over the coming years. Importantly, the revenue growth rate is expected to accelerate compared with the historical average of 9.96%, which is a key signal for growth-focused investors.
Those figures are meaningful in the context of an affordable growth screen. A company can show one good year of growth, but the more interesting setup is when growth is expected to persist or improve. The projected acceleration in revenue is a major reason Protagonist screens well. The screen is not just rewarding past performance; it is selecting a company where the growth story still has room to develop.
Valuation is less demanding than it first appears
On an absolute basis, Protagonist looks expensive. The trailing price-to-earnings ratio is 150.58, and the forward P/E ratio is negative because current earnings estimates for the next year remain under pressure. However, within the biotechnology industry the picture is different. The company is valued cheaper than 90% of its peer group based on the P/E ratio, and it is also cheaper than roughly 90% of its industry peers on an enterprise value to EBITDA basis and on a price to free cash flow basis.
The valuation rating of 5 out of 10 reflects this mix. The stock is not obviously cheap in dollar terms, but the combination of strong expected growth and lower relative multiples is what makes it eligible for an affordable growth screen. A low PEG ratio also supports the idea that the market is not fully compensating for the expected earnings growth. Investors who want to see the full breakdown of these fundamental metrics can review the fundamental analysis report.
Key affordable growth metrics
- Growth rating: 8/10
- Revenue growth last year: +34.81%
- Expected annual revenue growth: +68.61%
- Expected annual EPS growth: +36.32%
- Valuation rating: 5/10
- P/E cheaper than 90% of industry peers
- EV/EBITDA cheaper than 89.61% of industry peers
Health and profitability add a safety layer
Growth at a reasonable price is only useful if the company can survive the journey. Protagonist has no outstanding debt, which puts its debt ratios at the top of the industry. Its Altman-Z score of 133.88 indicates a very low near-term bankruptcy risk, and the current ratio of 21.71 gives the company ample liquidity to cover short-term obligations. Those factors explain the strong health rating of 8 out of 10.
Profitability is less consistent. The company posted positive earnings and positive operating cash flow in the past year, and its profit margin of 29.40% is among the best in the industry. However, it had negative earnings in four of the past five years, which is not unusual for a clinical-stage biopharmaceutical company but is worth noting as a risk. The return on assets and return on equity are also strong relative to peers, but the overall profitability rating of 5 out of 10 is a reminder that the company is still maturing.
For the affordable growth methodology, the mix of strong growth, reasonable relative valuation, and a clean balance sheet is the central qualification. The main limitation is clinical and regulatory execution. With lead programs in phase three development, the stock remains sensitive to trial data, regulatory decisions, and the pace of future investment. Investors should treat those catalysts as part of the risk profile rather than ignore them.
Other screens add confirmation
Protagonist’s growth profile is reinforced by additional quality-aware screens beyond the affordable growth methodology. The Fastest Growing Stocks screen confirms that PTGX combines strong recent earnings and sales growth with overall business quality, while the High EPS Growth screen supports the earnings momentum and financial health angle. The Revenue Growth Leaders screen further validates that the revenue expansion is both recent and multi-year in nature. These checks add independent support to the core case that PTGX is a growth story with enough fundamental substance to matter.
Investors who want to apply the same affordable growth methodology across a broader universe can explore the stock screener to find more companies that match these criteria.
Disclaimer: This article is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. Always conduct your own research and consider your risk tolerance before making investment decisions.
Read full article here »
View the Zacks #1 Rank List
Protagonist Therapeutics (NASDAQ:PTGX) Screens as an Affordable Growth Opportunity
The affordable growth screen looks for companies that combine strong expansion with a reasonable valuation, while still passing basic quality checks on profitability and financial health. PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX) (NASDAQ:PTGX) stands out under this methodology because its growth metrics are well above average, and despite a demanding headline earnings multiple, the stock still screens as attractively valued within its biotech peer group.
What the affordable growth screen targets
The idea behind an affordable growth strategy is to avoid paying any price for momentum. Fast-growing companies often trade at rich multiples, but the screen tries to identify situations where the market has not fully priced in future expansion. In practice, that means looking for:
Protagonist Therapeutics clears most of those hurdles. ChartMill gives the company a growth rating of 8 out of 10 and a health rating of 8 out of 10, with a more moderate profitability rating of 5 out of 10 and a valuation rating of 5 out of 10. The overall fundamental rating of 6 out of 10 reflects a business that is still clinical-stage, but the underlying metrics are notable for a company at this stage of development.
Growth is the main driver
The growth case for Protagonist is supported by both recent results and forward estimates. The company grew revenue by 34.81% over the last year and grew earnings per share by 47.14% in the same period. Analysts expect that momentum to continue, with EPS growth of 36.32% per year and revenue growth of 68.61% per year on average over the coming years. Importantly, the revenue growth rate is expected to accelerate compared with the historical average of 9.96%, which is a key signal for growth-focused investors.
Those figures are meaningful in the context of an affordable growth screen. A company can show one good year of growth, but the more interesting setup is when growth is expected to persist or improve. The projected acceleration in revenue is a major reason Protagonist screens well. The screen is not just rewarding past performance; it is selecting a company where the growth story still has room to develop.
Valuation is less demanding than it first appears
On an absolute basis, Protagonist looks expensive. The trailing price-to-earnings ratio is 150.58, and the forward P/E ratio is negative because current earnings estimates for the next year remain under pressure. However, within the biotechnology industry the picture is different. The company is valued cheaper than 90% of its peer group based on the P/E ratio, and it is also cheaper than roughly 90% of its industry peers on an enterprise value to EBITDA basis and on a price to free cash flow basis.
The valuation rating of 5 out of 10 reflects this mix. The stock is not obviously cheap in dollar terms, but the combination of strong expected growth and lower relative multiples is what makes it eligible for an affordable growth screen. A low PEG ratio also supports the idea that the market is not fully compensating for the expected earnings growth. Investors who want to see the full breakdown of these fundamental metrics can review the fundamental analysis report.
Key affordable growth metrics
Health and profitability add a safety layer
Growth at a reasonable price is only useful if the company can survive the journey. Protagonist has no outstanding debt, which puts its debt ratios at the top of the industry. Its Altman-Z score of 133.88 indicates a very low near-term bankruptcy risk, and the current ratio of 21.71 gives the company ample liquidity to cover short-term obligations. Those factors explain the strong health rating of 8 out of 10.
Profitability is less consistent. The company posted positive earnings and positive operating cash flow in the past year, and its profit margin of 29.40% is among the best in the industry. However, it had negative earnings in four of the past five years, which is not unusual for a clinical-stage biopharmaceutical company but is worth noting as a risk. The return on assets and return on equity are also strong relative to peers, but the overall profitability rating of 5 out of 10 is a reminder that the company is still maturing.
For the affordable growth methodology, the mix of strong growth, reasonable relative valuation, and a clean balance sheet is the central qualification. The main limitation is clinical and regulatory execution. With lead programs in phase three development, the stock remains sensitive to trial data, regulatory decisions, and the pace of future investment. Investors should treat those catalysts as part of the risk profile rather than ignore them.
Other screens add confirmation
Protagonist’s growth profile is reinforced by additional quality-aware screens beyond the affordable growth methodology. The Fastest Growing Stocks screen confirms that PTGX combines strong recent earnings and sales growth with overall business quality, while the High EPS Growth screen supports the earnings momentum and financial health angle. The Revenue Growth Leaders screen further validates that the revenue expansion is both recent and multi-year in nature. These checks add independent support to the core case that PTGX is a growth story with enough fundamental substance to matter.
Investors who want to apply the same affordable growth methodology across a broader universe can explore the stock screener to find more companies that match these criteria.
Disclaimer: This article is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. Always conduct your own research and consider your risk tolerance before making investment decisions.
Read full article here »